# Pharmacokinetic Drug-Drug Interaction Study of Rucaparib

> **NCT02740712** · PHASE1 · COMPLETED · sponsor: **pharmaand GmbH** · enrollment: 17 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Caffeine
- **DRUG:** Warfarin
- **DRUG:** Omeprazole
- **DRUG:** Midazolam
- **DRUG:** digoxin
- **DRUG:** Vitamin K
- **DRUG:** Rucaparib

## Key facts

- **NCT ID:** NCT02740712
- **Lead sponsor:** pharmaand GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-03
- **Final completion:** 2019-09
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02740712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02740712, "Pharmacokinetic Drug-Drug Interaction Study of Rucaparib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02740712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*